Table 4.

Characterisation of patients with gastric mucosa-associated lymphoid tissue (MALT) lymphoma at stage EI who have relapsed

	Sex	Age (years)	HP	Therapy	Time to relapse (months)	HP reinfection	Local of relapse	Relapse therapy	Response	Additional therapies	End of follow-up	DFS (months)
1	F	45	Yes	HP eradication	14	Yes	Gastric	HP eradication	No remission	RCHOP Radiation	Alive without disease	41
2	F	29	Yes	HP eradication	15	Yes	Gastric	HP eradication	Remission		Alive without disease	153
3	M	58	Yes	HP eradication	30	No	Upper limb mass and perigastric lymph nodes	RCHOP	Remission		Alive without disease	37
4	M	69	Yes	HP eradication	89	Yes	Gastric	HP eradication	Remission		Alive without disease	6
5	M	61	Yes	HP eradication	14	No	Gastric and perigastric lymph nodes	CVP	Remission		Dead without disease	114
6	M	57	No	HP eradication Chlorambucila	24	No	Gastric	Rituximab	Remission	Radiation (2nd relapse)	Alive without disease	44
7	F	46	No	HP eradication Chlorambucila	16	No	Gastric	RCHOP	Remission		Alive without disease	56
8	M	49	Yes	HP eradication	11	No	Gastric	Radiation	Remission		Alive without disease	37
9	F	42	Yes	HP eradication	9	Yes	Gastric	HP eradication	Remission		Alive without disease	29
10	M	56	Yes	HP eradication	11	Yes	Gastric	HP eradication	Remission	Chlorambucil (2nd relapse) RCVP (3th relapse)	Alive without disease	33
11	F	78	Yes	HP eradication	4	Yes	Gastric	HP eradication	Remission		Alive without disease	18

CVP: cyclophosphamide, vincristine, prednisone; DFS: disease free survival; F/M: female/male; HP: Helicobacter pylori; RCHOP-rituximab, cyclophosphamide, doxorubicin (hydroxydaunomycin), vincristine (oncovin), prednisolone; RCVP: rituximab, cyclophosphamide, vincristine, prednisone.

^aThese patients did not achieve complete remission after HP eradication and watch-and-wait strategy, and thus received an alternative therapy.